Thus reversibility of MEKi-resistance and the consequences of MEKi withdrawal may be influenced by the nature of the particular amplified oncogene - BRAF or KRAS - highlighting again the challenges of targeting cancers with KRAS mutations. The gene discussed is BRAF; the disease is cancer.